Marker Therapeutics Inc (MRKR)

[Epicare]

Thank you PL as always! I just like to add scientific information regarding MT-601. I am sure most of long MRKR investors have already known this. So I post here for those newbies who just jumped on MRKR wagon.

The major difference between MT-501 and MT-601 is adding WT1 (Wilm's tumor gene 1) to the cocktail. WT1 is not normally expressed in lymphocytes and many other normal tissues. WT1 is one of the most widespread tumor antigens present in many human malignancies, including lymphoma, AML and approximately 30+% of solid tumors.Therefore, it was a smart move for MRKR to add WT1 to maximize its anti-cancer potential in a much wider spectrum of cancer types.

Among hematopoietic cancers, WT1 RNA expression was detected in 90% chronic myeloid leukemia (CML), 87% of acute myeloid leukemia (AML), 68% acute lymphoblastic leukemia (ALL) and 30% of malignant lymphomas. Among lymphoma, WT1 expression is usually found in higher grade lymphoma with aggressive behaviors and worst prognosis. For example, WT1 expression was found in 80% Burkitt lymphomas, 75% ALK-positive ALCL, 45% ALK-negative ALCL, 50% lymphoblastic lymphomas, and 33% DLBCL.

Among solid tumors, WT1 expression was seen in approximately 1/3 of all solid tumors. The expression of WT1 is seen in ovarian serous carcinoma (95%), malignant mesothelioma (85%), pancreatic cancer (78%), uterine sarcoma (75%), glioblastoma (68%), lung NSCLC (50%), breast cancer (30%), and endometrial cancer (25%).

Recent MRKR pre-clinical study to show MT-601 effectiveness in lymphoma is very encouraging, given that lymphoma is not a high expressor for WT1 (only those 30% of highly aggressive lymphomas). I definitely anticipate better, or at least equivalent, results in AML or pancreatic cancer.

Have a wonderful day everyone!